In middle aged 12-month-old 3xTg-AD mice, CEF rescued cognitive decline but had no pronounced effect on APP processing, overall Aβ species levels (except for the increase in Aβ40 levels in the CEF-treated mice), or plaque pathology. This evidence concerns the gene APP and Alzheimer disease.